In This Article:
Chesnot / Getty Images
Key Takeaways
-
Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.
-
The companies plan to provide further details about the research at a scientific forum in 2025.
-
Teva and Sanofi said they would start a Phase 3 study of the treatment pending discussions with regulators.
-
Both pharmaeuticals companies' U.S.-traded stocks gained after the news Tuesday, with Teva at its highest level in six years.
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn’s disease.
A press release from Teva on Tuesday said the Phase 2b trial of the human monoclonal antibody duvakitug found that the substance met the primary endpoints. It noted that UC patients given a low dosage and high dosage of the drug achieved clinical remission of 36.2% and 47.8%, respectively, higher than those receiving a placebo.
For Crohn's disease patients, the results were 26.1% and 47.8%, respectively, also above those taking a placebo.
First Study of Its Type for Crohn's Disease, Teva Says
Teva said that this was “the first and only randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in [Crohn's disease].” It added that the companies expect to give detailed results at a scientific forum next year.
Dr, Houman Ashrafian, head of research & development at Sanofi, said the results show “that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease.”
Teva and Sanofi said they plan to launch a Phase 3 trial for duvakitug pending regulatory discussions.
Teva's U.S.-traded shares were at their highest level in six years Tuesday, up more than 26% at $20.88 recently. The stock has almost doubled in price this year. Sanofi's U.S.-traded shares moved up more than 7% to $49.10.
Read the original article on Investopedia